title: Vaccination against pseudorabies with glycoprotein gI+ or glycoprotein gI- vaccine.
abstract: Subunit pseudorabies vaccines that contained only purified glycoproteins of either of 2 strains of pseudorabies virus (PRV) were prepared and subsequently tested for safety and efficacy. The strains of virus used for vaccine production differed in at least 2 properties. One strain (Kojnok) was virulent for pigs and was believed to code for the entire complement of viral glycoproteins. The other (Kaplan) was a deletion mutant that was unable to code for structural viral glycoproteins gI and gp63. Purified glycoproteins were dispersed in an oil-in-water emulsion and were administered IM to pigs. Both vaccines were found to be safe and effective immunogens. Neither caused any local or general reactions, as verified by examination of the injection site (local safety) and by vaccination of pregnant sows in PRV-infected and noninfected herds. Sows vaccinated with the gI+ or gI- vaccine protected their pigs at levels of 93 and 92%, respectively, against a severe challenge exposure that killed 98% of pigs born from nonvaccinated sows. Vaccinated pigs were tested for active immunity by intranasal challenge exposure with the NIA 3 strain. Protection was quantitated by measuring the relative daily weight difference, expressed in percent per day, between vaccinated and control pigs during the first week after challenge exposure (delta G7); the estimated differences were 2.25 and 2.13% for gI+ and gI- vaccines, respectively. The absence of gI and gp63 did not affect the efficacy of this type of subunit glycoprotein vaccines.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Rhõne Mérieux, Laboratoire IFFA, Lyon.
authors.forename: J
authors.initials: J
authors.lastname: Vandeputte
authors.forename: G
authors.initials: G
authors.lastname: Chappuis
authors.forename: D
authors.initials: D
authors.lastname: Fargeaud
authors.forename: P
authors.initials: P
authors.lastname: Précausta
authors.forename: F
authors.initials: F
authors.lastname: Guillemin
authors.forename: A
authors.initials: A
authors.lastname: Brun
authors.forename: P
authors.initials: P
authors.lastname: Desmettre
authors.forename: C
authors.initials: C
authors.lastname: Stellmann
mesh_terms: D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D011558:Herpesvirus 1, Suid / Q000032:analysis / Q000276:immunology* / Q000472:pathogenicity; D005779:Immunodiffusion / Q000662:veterinary; D011557:Pseudorabies / Q000188:drug therapy / Q000517:prevention & control*; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary*; D014759:Viral Envelope Proteins / Q000276:immunology / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000032:analysis / Q000276:immunology*; D014774:Virulence
chemical_list: D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C042966:pseudorabies virus glycoproteins